Evidence map›Paper›PMID 39776201›Full record

ArticleArchives of toxicology2025

Non-invasive in vitro NAM for the detection of reversible and irreversible eye damage after chemical exposure for GHS classification purposes (ImAi).

Nicola Knetzger, Norman Ertych, Tanja Burgdorf, Joelle Beranek, Michael Oelgeschläger, Jana Wächter, Annika Horchler, Stefanie Gier, Maike Windbergs, Susann Fayyaz and 3 more

Abstract read
In one paragraph

Article in Archives of toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Advances in Cytotoxicity Testing: From In Vitro Assays to In Silico Models.International journal of molecular sciences · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Nicola KnetzgerTranslational Center Regenerative Therapies (TLC-RT), Fraunhofer Institute for Silicate Research (ISC), Röntgenring 12, 97070, Würzburg, Germany.
Norman ErtychDepartment Experimental Toxicology and ZEBET, German Centre for the Protection of Laboratory Animals (Bf3R), German Federal Institute for Risk Assessment (BfR), Berlin, Germany.
Tanja BurgdorfDepartment Experimental Toxicology and ZEBET, German Centre for the Protection of Laboratory Animals (Bf3R), German Federal Institute for Risk Assessment (BfR), Berlin, Germany.
Joelle BeranekDepartment Experimental Toxicology and ZEBET, German Centre for the Protection of Laboratory Animals (Bf3R), German Federal Institute for Risk Assessment (BfR), Berlin, Germany.
Michael OelgeschlägerDepartment Experimental Toxicology and ZEBET, German Centre for the Protection of Laboratory Animals (Bf3R), German Federal Institute for Risk Assessment (BfR), Berlin, Germany.
Jana WächterInstitute of Pharmaceutical Technology, Goethe University Frankfurt (GU), Frankfurt Am Main, Germany.
Annika HorchlerInstitute of Pharmaceutical Technology, Goethe University Frankfurt (GU), Frankfurt Am Main, Germany.
Stefanie GierInstitute of Pharmaceutical Technology, Goethe University Frankfurt (GU), Frankfurt Am Main, Germany.
Maike WindbergsInstitute of Pharmaceutical Technology, Goethe University Frankfurt (GU), Frankfurt Am Main, Germany.
Susann FayyazClariant Produkte (Deutschland) GmbH, Frankfurt Am Main, Germany.
Fabian A GrimmClariant Produkte (Deutschland) GmbH, Frankfurt Am Main, Germany.
Georg WioraCourage + Khazaka Electronic GmbH (C+K), Cologne, Germany.
Christian LotzTranslational Center Regenerative Therapies (TLC-RT), Fraunhofer Institute for Silicate Research (ISC), Röntgenring 12, 97070, Würzburg, Germany. Christian.lotz@isc.fraunhofer.de.ORCID 0000-0003-3106-1159

Funding

Bundesministerium für Bildung und Forschung ImAi 031L0227BBundesministerium für Bildung und Forschung ImAi 031L0227DBundesministerium für Bildung und Forschung ImAi 161L0227ABundesministerium für Bildung und Forschung ImAi 161L0227CBundesministerium für Bildung und Forschung ImAi-2 16LW0367Bundesministerium für Bildung und Forschung ImAi-2 16LW0368Bundesministerium für Bildung und Forschung ImAi-2 16LW0369
6 · The paper itself

Abstract

The potential risk of chemicals to the human eye is assessed by adopted test guidelines (TGs) for regulatory purposes to ensure consumer safety. Over the past decade, the Organization for Economic Co-operation and Development (OECD) has approved new approach methodologies (NAMs) to predict chemical eye damage. However, existing NAMs remain associated with limitations: First, no full replacement of the in vivo Draize eye test due to limited predictability of severe/mild damage was reached. Second, the existing NAMs do not allow reliable differentiation between reversible and irreversible eye damage. Especially the prediction of tissue recovery remains challenging in vitro. Existing in vitro NAMs are based on destructive analysis with no consideration of tissue recovery. In this study, we developed a standalone eye-irritation test method based on non-invasive impedance spectroscopy (ImAi) to discriminate between damaging and irritating chemicals. Tissue effects were analyzed via transepithelial electrical resistance (TEER) measurements of human in vitro epithelial models over 14 days. The TEER was performed using a developed impedance spectrometer. For development of the EIT, a chemical reference list of 329 chemicals was compiled. The applicability of the ImAi-test was exemplified by the discrimination of Cat. 1 vs. Cat. 2 for 23 reference chemicals. Correct classification was achieved for 90.9% of Cat. 1 and 83.3% of Cat. 2 chemicals. Our non-invasive in vitro test overcomes the limitations of Cat. 2 classification of the existing in vitro methods and provides for the first time a non-animal test method that can fully replace the Draize eye test.

Indexed as

Dielectric SpectroscopyEyeIrritantsToxicity TestsAnimal Testing AlternativesHumansRisk AssessmentIrritantsEye irritationImpedance spectroscopyNAMNon-invasive

Identifiers

PMID39776201
PMCPMC11821759

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.